Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein

Abstract

Hyperglycemia is associated with greater hematoma expansion and poor clinical outcomes after intracerebral hemorrhage. We show that cerebral hematoma expansion triggered by intracerebral infusion of autologous blood is greater in diabetic rats and mice compared to nondiabetic controls and that this augmented expansion is ameliorated by plasma kallikrein (PK) inhibition or deficiency. Intracerebral injection of purified PK augmented hematoma expansion in both diabetic and acutely hyperglycemic rats, whereas injection of bradykinin, plasmin or tissue plasminogen activator did not elicit such a response. This response, which occurs rapidly, was prevented by co-injection of the glycoprotein VI agonist convulxin and was mimicked by glycoprotein VI inhibition or deficiency, implicating an effect of PK on inhibiting platelet aggregation. We show that PK inhibits collagen-induced platelet aggregation by binding collagen, a response enhanced by elevated glucose concentrations. The effect of hyperglycemia on hematoma expansion and PK-mediated inhibition of platelet aggregation could be mimicked by infusing mannitol. These findings suggest that hyperglycemia auguments cerebral hematoma expansion by PK-mediated osmotic-sensitive inhibition of hemostasis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Effect of kallikrein-kinin inhibition on blood-induced hematoma expansion in brains of diabetic animals.
Figure 2: Effect of intracerebral injection of PK on hematoma expansion in brains of diabetic or acutely hyperglycemic rats.
Figure 3: Effect of PK on platelet aggregation and the effect of GPVI on cerebral hematoma expansion in animals.
Figure 4: Effect of osmolarity on the binding of PK to collagen, collagen-stimulated platelet aggregation and hematoma expansion.

Similar content being viewed by others

Evdokia Dimitriadis, Daniel L. Rolnik, … Ellen Menkhorst

References

  1. Feigin, V.L., Lawes, C.M., Bennett, D.A. & Anderson, C.S. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2, 43–53 (2003).

    Article  Google Scholar 

  2. Arboix, A., Massons, J., Garcia-Eroles, L., Oliveres, M. & Targa, C. Diabetes is an independent risk factor for in-hospital mortality from acute spontaneous intracerebral hemorrhage. Diabetes Care 23, 1527–1532 (2000).

    Article  CAS  Google Scholar 

  3. Kimura, K. et al. Hyperglycemia independently increases the risk of early death in acute spontaneous intracerebral hemorrhage. J. Neurol. Sci. 255, 90–94 (2007).

    Article  CAS  Google Scholar 

  4. Godoy, D.A., Pinero, G.R., Svampa, S., Papa, F. & Di Napoli, M. Hyperglycemia and short-term outcome in patients with spontaneous intracerebral hemorrhage. Neurocrit. Care 9, 217–229 (2008).

    Article  CAS  Google Scholar 

  5. Lee, S.H. et al. Effects of glucose level on early and long-term mortality after intracerebral haemorrhage: the Acute Brain Bleeding Analysis Study. Diabetologia 53, 429–434 (2010).

    Article  CAS  Google Scholar 

  6. Demchuk, A.M. et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 30, 34–39 (1999).

    Article  CAS  Google Scholar 

  7. Poppe, A.Y. et al. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care 32, 617–622 (2009).

    Article  Google Scholar 

  8. Broderick, J.P., Brott, T.G., Duldner, J.E., Tomsick, T. & Huster, G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 24, 987–993 (1993).

    Article  CAS  Google Scholar 

  9. Davis, S.M. et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66, 1175–1181 (2006).

    Article  CAS  Google Scholar 

  10. Kazui, S., Minematsu, K., Yamamoto, H., Sawada, T. & Yamaguchi, T. Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke 28, 2370–2375 (1997).

    Article  CAS  Google Scholar 

  11. Passero, S., Ciacci, G. & Ulivelli, M. The influence of diabetes and hyperglycemia on clinical course after intracerebral hemorrhage. Neurology 61, 1351–1356 (2003).

    Article  Google Scholar 

  12. Fogelholm, R., Murros, K., Rissanen, A. & Avikainen, S. Admission blood glucose and short term survival in primary intracerebral haemorrhage: a population based study. J. Neurol. Neurosurg. Psychiatry 76, 349–353 (2005).

    Article  CAS  Google Scholar 

  13. Broderick, J.P. et al. Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke 38, 1072–1075 (2007).

    Article  CAS  Google Scholar 

  14. Stead, L.G. et al. Emergency Department hyperglycemia as a predictor of early mortality and worse functional outcome after intracerebral hemorrhage. Neurocrit. Care 13, 67–74 (2010).

    Article  CAS  Google Scholar 

  15. Scott, J.F. et al. Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke. Lancet 353, 376–377 (1999).

    Article  CAS  Google Scholar 

  16. Gray, C.S. et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 6, 397–406 (2007).

    Article  CAS  Google Scholar 

  17. Bruno, A. et al. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke 39, 384–389 (2008).

    Article  CAS  Google Scholar 

  18. McCormick, M.T., Muir, K.W., Gray, C.S. & Walters, M.R. Management of hyperglycemia in acute stroke: how, when, and for whom? Stroke 39, 2177–2185 (2008).

    Article  Google Scholar 

  19. Godoy, D.A., Pinero, G.R., Svampa, S., Papa, F. & Di Napoli, M. Early hyperglycemia and intravenous insulin-the rationale and management of hyperglycemia for spontaneous intracerebral hemorrhage patients: is time for change? Neurocrit. Care 10, 150–153 (2009).

    Article  Google Scholar 

  20. Broderick, J. et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38, 2001–2023 (2007).

    Article  Google Scholar 

  21. Gao, B.B. et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 13, 181–188 (2007).

    Article  CAS  Google Scholar 

  22. Schmaier, A.H. & McCrae, K.R. The plasma kallikrein-kinin system: its evolution from contact activation. J. Thromb. Haemost. 5, 2323–2329 (2007).

    Article  CAS  Google Scholar 

  23. Phipps, J.A. et al. Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension 53, 175–181 (2009).

    Article  CAS  Google Scholar 

  24. Acar, K., Yagci, M., Sucak, G.T. & Haznedar, R. Isolated prolonged activated partial thromboplastin time in an asymptomatic patient: Fletcher factor deficiency. Thromb. Res. 118, 765–766 (2006).

    Article  CAS  Google Scholar 

  25. Asmis, L.M., Sulzer, I., Furlan, M. & Lammle, B. Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thromb. Res. 105, 463–470 (2002).

    Article  CAS  Google Scholar 

  26. Lippi, G. et al. Epidemiological association between fasting plasma glucose and shortened APTT. Clin. Biochem. 42, 118–120 (2009).

    Article  CAS  Google Scholar 

  27. Qureshi, A.I. et al. Spontaneous intracerebral hemorrhage. N. Engl. J. Med. 344, 1450–1460 (2001).

    Article  CAS  Google Scholar 

  28. Gallimore, M.J., Fareid, E. & Stormorken, H. The purification of a human plasma kallikrein with weak plasminogen activator activity. Thromb. Res. 12, 409–420 (1978).

    Article  CAS  Google Scholar 

  29. Ruggeri, Z.M. & Mendolicchio, G.L. Adhesion mechanisms in platelet function. Circ. Res. 100, 1673–1685 (2007).

    Article  CAS  Google Scholar 

  30. Toyoda, K. et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 65, 1000–1004 (2005).

    Article  CAS  Google Scholar 

  31. Nieswandt, B., Aktas, B., Moers, A. & Sachs, U.J. Platelets in atherothrombosis: lessons from mouse models. J. Thromb. Haemost. 3, 1725–1736 (2005).

    Article  CAS  Google Scholar 

  32. Kehrel, B. et al. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood 91, 491–499 (1998).

    CAS  PubMed  Google Scholar 

  33. Nieswandt, B. & Watson, S.P. Platelet-collagen interaction: is GPVI the central receptor? Blood 102, 449–461 (2003).

    Article  CAS  Google Scholar 

  34. Arthur, J.F., Dunkley, S. & Andrews, R.K. Platelet glycoprotein VI-related clinical defects. Br. J. Haematol. 139, 363–372 (2007).

    Article  CAS  Google Scholar 

  35. Nieswandt, B. et al. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain. J. Biol. Chem. 275, 23998–24002 (2000).

    Article  CAS  Google Scholar 

  36. Miura, Y., Takahashi, T., Jung, S.M. & Moroi, M. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J. Biol. Chem. 277, 46197–46204 (2002).

    Article  CAS  Google Scholar 

  37. Stultz, C.M. & Edelman, E.R. A structural model that explains the effects of hyperglycemia on collagenolysis. Biophys. J. 85, 2198–2204 (2003).

    Article  CAS  Google Scholar 

  38. Bhalla, A. et al. Influence of raised plasma osmolality on clinical outcome after acute stroke. Stroke 31, 2043–2048 (2000).

    Article  CAS  Google Scholar 

  39. James, M.L., Warner, D.S. & Laskowitz, D.T. Preclinical models of intracerebral hemorrhage: a translational perspective. Neurocrit. Care 9, 139–152 (2008).

    Article  Google Scholar 

  40. Walkowiak, B., Kesy, A. & Michalec, L. Microplate reader—a convenient tool in studies of blood coagulation. Thromb. Res. 87, 95–103 (1997).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the US National Institutes of Health (grants EY19029, DK36836, HL090132, HL87203 and HL07917) and the American Heart Association (0855905D and 0840043N).

Author information

Authors and Affiliations

Authors

Contributions

J.L. initiated, designed and conducted most of the experiments and wrote the manuscript. B.-B.G. contributed to the design and performance of animal studies, biochemical analyses, platelet studies and manuscript writing. A.C.C. contributed to animal studies. P.B. and R.F. designed and performed studies using platelet aggregometer and contributed to data interpretation. T.J.C. and S.S. contributed to data interpretation and manuscript editing. E.P.F. designed and supervised the entire study and contributed to manuscript writing.

Corresponding author

Correspondence to Edward P Feener.

Ethics declarations

Competing interests

Tamie J. Chilcote and Sukanto Sinha are employees of and shareholders in ActiveSite Pharmaceuticals, which provided ASP-440. The Joslin Diabetes Center and ActiveSite Pharmaceuticals have submitted a patent application to the US Patent and Trademark Office and the European Patent Office on the methods for treatment of kallikrein-related disorders.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–8 and Supplementary Methods (PDF 265 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, J., Gao, BB., Clermont, A. et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med 17, 206–210 (2011). https://doi.org/10.1038/nm.2295

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2295

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing